Anti-scarring properties of different tryptophan derivatives.

Hypertrophic scars are associated with prolonged extracellular matrix (ECM) production, aberrant ECM degradation and high tissue cellularity. Routinely used antifibrotic strategies aim to reduce ECM deposition and enhance matrix remodeling. Our previous study investigating the antifibrotic effects o...

Full description

Bibliographic Details
Main Authors: Malihe-Sadat Poormasjedi-Meibod, Ryan Hartwell, Ruhangiz Taghi Kilani, Aziz Ghahary
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3956813?pdf=render
_version_ 1819076051678003200
author Malihe-Sadat Poormasjedi-Meibod
Ryan Hartwell
Ruhangiz Taghi Kilani
Aziz Ghahary
author_facet Malihe-Sadat Poormasjedi-Meibod
Ryan Hartwell
Ruhangiz Taghi Kilani
Aziz Ghahary
author_sort Malihe-Sadat Poormasjedi-Meibod
collection DOAJ
description Hypertrophic scars are associated with prolonged extracellular matrix (ECM) production, aberrant ECM degradation and high tissue cellularity. Routinely used antifibrotic strategies aim to reduce ECM deposition and enhance matrix remodeling. Our previous study investigating the antifibrotic effects of indoleamine2, 3 dioxygenase (IDO) led to the identification of kynurenine (Kyn) as an antiscarring agent. A topical antifibrogenic therapy using Kyn is very attractive; however, it is well established that Kyn passes the blood brain barrier (BBB) which causes complications including excitatory neuronal death. Here we investigated the antiscarring properties of kynurenic acid (KynA), a downstream end product of Kyn that is unlikely to pass the BBB, as an effective and safe replacement for Kyn. Our results indicated that while not having any adverse effect on dermal cell viability, KynA significantly increases the expression of matrix metalloproteinases (MMP1 and MMP3) and suppresses the production of type-I collagen and fibronectin by fibroblasts. Topical application of cream containing KynA in fibrotic rabbit ear significantly decreased scar elevation index (1.13±0.13 vs. 1.61±0.12) and tissue cellularity (221.38±21.7 vs. 314.56±8.66 cells/hpf) in KynA treated wounds compared to controls. KynA treated wounds exhibited lower levels of collagen deposition which is accompanied with a significant decrease in type-I collagen and fibronectin expression, as well as an increase in MMP1 expression compared to untreated wounds or wounds treated with cream only. The results of this study provided evidence for the first time that KynA is promising candidate antifibrogenic agent to improve healing outcome in patients at risk of hypertrophic scarring.
first_indexed 2024-12-21T18:35:10Z
format Article
id doaj.art-df91f8a8e1df4d81a2c3a33030a068d8
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-21T18:35:10Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-df91f8a8e1df4d81a2c3a33030a068d82022-12-21T18:54:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0193e9195510.1371/journal.pone.0091955Anti-scarring properties of different tryptophan derivatives.Malihe-Sadat Poormasjedi-MeibodRyan HartwellRuhangiz Taghi KilaniAziz GhaharyHypertrophic scars are associated with prolonged extracellular matrix (ECM) production, aberrant ECM degradation and high tissue cellularity. Routinely used antifibrotic strategies aim to reduce ECM deposition and enhance matrix remodeling. Our previous study investigating the antifibrotic effects of indoleamine2, 3 dioxygenase (IDO) led to the identification of kynurenine (Kyn) as an antiscarring agent. A topical antifibrogenic therapy using Kyn is very attractive; however, it is well established that Kyn passes the blood brain barrier (BBB) which causes complications including excitatory neuronal death. Here we investigated the antiscarring properties of kynurenic acid (KynA), a downstream end product of Kyn that is unlikely to pass the BBB, as an effective and safe replacement for Kyn. Our results indicated that while not having any adverse effect on dermal cell viability, KynA significantly increases the expression of matrix metalloproteinases (MMP1 and MMP3) and suppresses the production of type-I collagen and fibronectin by fibroblasts. Topical application of cream containing KynA in fibrotic rabbit ear significantly decreased scar elevation index (1.13±0.13 vs. 1.61±0.12) and tissue cellularity (221.38±21.7 vs. 314.56±8.66 cells/hpf) in KynA treated wounds compared to controls. KynA treated wounds exhibited lower levels of collagen deposition which is accompanied with a significant decrease in type-I collagen and fibronectin expression, as well as an increase in MMP1 expression compared to untreated wounds or wounds treated with cream only. The results of this study provided evidence for the first time that KynA is promising candidate antifibrogenic agent to improve healing outcome in patients at risk of hypertrophic scarring.http://europepmc.org/articles/PMC3956813?pdf=render
spellingShingle Malihe-Sadat Poormasjedi-Meibod
Ryan Hartwell
Ruhangiz Taghi Kilani
Aziz Ghahary
Anti-scarring properties of different tryptophan derivatives.
PLoS ONE
title Anti-scarring properties of different tryptophan derivatives.
title_full Anti-scarring properties of different tryptophan derivatives.
title_fullStr Anti-scarring properties of different tryptophan derivatives.
title_full_unstemmed Anti-scarring properties of different tryptophan derivatives.
title_short Anti-scarring properties of different tryptophan derivatives.
title_sort anti scarring properties of different tryptophan derivatives
url http://europepmc.org/articles/PMC3956813?pdf=render
work_keys_str_mv AT malihesadatpoormasjedimeibod antiscarringpropertiesofdifferenttryptophanderivatives
AT ryanhartwell antiscarringpropertiesofdifferenttryptophanderivatives
AT ruhangiztaghikilani antiscarringpropertiesofdifferenttryptophanderivatives
AT azizghahary antiscarringpropertiesofdifferenttryptophanderivatives